Ebola hemorrhagic fever: a paradigm of multiorgan dysfunction

References

• Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ. Filoviridae: Marburg and Ebola viruses. Fields virology4th ed, DM Knipe, PM Howley, DE Griffin, RA Lamb, MA Martin, B Roizman, et al. Lippincott Williams & Wilkins, Philadelphia, PA 2001; 1279–304
   Google Scholar
• Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003; 3: 677–85
   PubMed Web of Science ®Google Scholar
• Mühlberger E, Weik M, Volchkov VE, Klenk HD, Becker S. Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. J Virol 1999; 73: 2333–42
   PubMed Web of Science ®Google Scholar
• Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol 2002; 76: 4855–65
   PubMed Web of Science ®Google Scholar
• Hoenen T, Volchkov V, Kolesnikova L, Mittler E, Timmins J, Ottmann M, et al. VP40 octamers are essential for Ebola virus replication. J Virol 2005; 79: 1898–905
   PubMed Web of Science ®Google Scholar
• Ruthel G, Demmin GL, Kallstrom G, Javid MP, Badie SS, Will AB, et al. Association of Ebola virus matrix protein VP40 with microtubules. J Virol 2005; 79: 4709–19
   PubMed Web of Science ®Google Scholar
• Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 1998; 72: 3155–60
   PubMed Web of Science ®Google Scholar
• Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, et al. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci USA 1997; 94: 14764–9
   PubMed Web of Science ®Google Scholar
• Feldmann H, Volchkov VE, Volchkova VA, Ströher U, Klenk HD. Biosynthesis and role of filoviral glycoproteins. J Gen Virol 2001; 82: 2839–48
   PubMed Web of Science ®Google Scholar
• Volchkova VA, Feldmann H, Klenk HD, Volchkov VE. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 1998; 250: 408–14
   PubMed Web of Science ®Google Scholar
• Volchkova VA, Klenk HD, Volchkov VE. Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 1999; 265: 164–71
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Volchkova VA, Slenczka W, Klenk HD, Feldmann H. Release of viral glycoproteins during Ebola virus infection. Virology 1998; 245: 110–9
   PubMed Web of Science ®Google Scholar
• Dolnik O, Volchkova V, Garten W, Carbonnelle C, Becker S, Kahnt J, et al. Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 2004; 23: 2175–84
   PubMed Web of Science ®Google Scholar
• Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc Natl Acad Sci USA 2000; 97: 13871–6
   PubMed Web of Science ®Google Scholar
• Chandran, K, Sullivan, NJ, Felbor, U, Whelan, SP, Cunningham, JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 2005;308:1643–5.
   PubMed Web of Science ®Google Scholar
• Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 2000; 6: 886–9
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, Nabel E, et al. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J Virol 2005; 79: 547–53
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu L, Sun Y, Nabel GJ. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell 2002; 10: 307–16
   PubMed Web of Science ®Google Scholar
• Jasenosky LD, Kawaoka Y. Filovirus budding. Virus Res 2004; 106: 181–8
   PubMed Web of Science ®Google Scholar
• Basler CF, Palese P. Modulation of innate immunity by filoviruses. Ebola and Marburg viruses: molecular and cellular biology, HD Klenk, H Feldmann. Horizon Bioscience, NorfolkUK 2004; 305–49
   Google Scholar
• Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci USA 2000; 97: 12289–94
   PubMed Web of Science ®Google Scholar
• Basler CF, Mikulasova A, Martinez-Sobrido L, Paragas J, Muhlberger E, Bray M, et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol 2003; 77: 7945–56
   PubMed Web of Science ®Google Scholar
• Kissling RE, Robinson RQ, Murphy FA, Whitfield SG. Agent of disease contracted from green monkeys. Science 1968; 160: 888–90
   PubMed Web of Science ®Google Scholar
• Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, Meyers AM, et al. Outbreak of Marburg virus disease in Johannesburg. BMJ 1975; iv: 489–93
   Google Scholar
• Bowen ET, Lloyd G, Harris WJ, Platt GS, Baskerville A, Vella EE. Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent. Lancet 1977; i: 571–3
   Google Scholar
• Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978; 56: 247–70
   PubMed Web of Science ®Google Scholar
• Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 1983; 61: 997–1003
   PubMed Web of Science ®Google Scholar
• Heymann DL, Weisfeld JS, Webb PA, Johnson KM, Cairns T, Berquist H. Ebola hemorrhagic fever: Tandala, Zaire, 1977–1978. J Infect Dis 1980; 142: 372–6
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert TW, Dalgard DW, Johnson ED, Ksiazek TG, Hall WC, et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990; 335: 502–5
   PubMed Web of Science ®Google Scholar
• Outbreak of Ebola viral hemorrhagic fever – Zaire, 1995. MMWR Morb Mortal Wkly Rep 1995; 44: 381–2
   PubMedGoogle Scholar
• Le Guenno B, Formentry P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 1995; 345: 1271–4
   PubMed Web of Science ®Google Scholar
• Sanchez A, Ksiazek TG, Rollin PE, Peters CJ, Nichol ST, Khan AS, et al. Reemergence of Ebola virus in Africa. Emerg Infect Dis 1995; 1: 96–7
   PubMed Web of Science ®Google Scholar
• Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, Kerstiens B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179(Suppl 1)S76–86
   Google Scholar
• Ndayimirije N, Kindhauser MK. Marburg hemorrhagic fever in Angola – fighting fear and a lethal pathogen. N Engl J Med 2005; 352: 2155–7
   PubMed Web of Science ®Google Scholar
• Marburg hemorrhagic fever in Angola – update 22. World Health Organization. 17 June 2005. Available at: http://www.who.int/csr/don/2005_06_17/en/index.html. Accessed 19 June 2005.
   Google Scholar
• Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, Fulhorst CF, et al. Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 1999; 171(Suppl 1)S115–9
   Google Scholar
• Walsh PD, Abernethy KA, Bermejo M, Beyers R, De Wachter P, Akou ME, et al. Catastrophic ape decline in western equatorial Africa. Nature 2003; 422: 611–4
   PubMed Web of Science ®Google Scholar
• Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179(Suppl 1)S87–91
   PubMedGoogle Scholar
• Bennett D, Brown D. Ebola virus. BMJ 1995; 310: 1344–5
   PubMedGoogle Scholar
• Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004; 10: S110–21
   PubMed Web of Science ®Google Scholar
• Kagan E. Update on Ebola virus and its potential as a bioterrorism agent. Clin Pulm Med 2005; 12: 76–83
   Google Scholar
• Chepurnov AA, Chuev Iu P, P'Iankov OV, Efimova IV. The effect of some physical and chemical factors on inactivation of the Ebola virus. Vopr Virusol 1995; 40: 74–6, (In Russian.)
   PubMed Web of Science ®Google Scholar
• Viral hemorrhagic fever (VHF): current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, treatment, and prophylaxis: Center for Infectious Disease Research & Policy, University of Minnesota; 2005.
   Google Scholar
• Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999; 179(Suppl 1)S1–7
   PubMed Web of Science ®Google Scholar
• Sureau PH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev Infect Dis 1989; 11(Suppl 4)S790–3
   PubMedGoogle Scholar
• Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000; 355: 2210–5
   PubMed Web of Science ®Google Scholar
• Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol 2001; 124: 453–60
   PubMed Web of Science ®Google Scholar
• Ellis DS, Simpson IH, Francis DP, Knobloch J, Bowen ET, Lolik P, et al. Ultrastructure of Ebola virus particles in human liver. J Clin Pathol 1978; 31: 201–8
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res 1995; 39: 129–50
   PubMed Web of Science ®Google Scholar
• Zaki SR, Goldsmith CS. Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 1999; 235: 97–116
   PubMed Web of Science ®Google Scholar
• Baskerville A, Fisher-Hoch SP, Neild GH, Dowsett AB. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol 1985; 147: 199–209
   PubMed Web of Science ®Google Scholar
• Johnson E, Jaax N, White J, Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 1995; 76: 227–36
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges-Courbot M-C, Capron M, Lansoud-Soukate J, Debré P, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999; 5: 423–6
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Invest 2000; 80: 171–86
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 2003; 163: 2347–70
   PubMed Web of Science ®Google Scholar
• Villinger F, Rollin PE, Brar SS, Chikkala NF, Winter J, Sundstrom JB, et al. Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J Infect Dis 1999; 179(Suppl 1)S188–91
   PubMedGoogle Scholar
• Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 2002; 80: 169–79
   PubMed Web of Science ®Google Scholar
• Ryabchikova E, Kolesnikova L, Smolina M, Tkachev V, Pereboeva L, Baranova S, et al. Ebola virus infection in guinea pigs: presumable role of granulomatous inflammation in pathogenesis. Arch Virol 1996; 141: 909–21
   PubMed Web of Science ®Google Scholar
• Chepurnov AA, Dadaeva AA, Zhukov VA, Sizikov LP, Merzlikin NV. Change in biochemical and hemostatic indicators in guinea pigs upon administering Ebola virus preparations. Vopr Virusol 1997; 42: 171–5, (In Russian.)
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178: 651–61
   PubMed Web of Science ®Google Scholar
• Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax NK, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(Suppl 1)S203–17
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med 2004; 2004: 1–24
   Google Scholar
• Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8: 503–7
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines 2003; 2: 89–101
   Google Scholar
• Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 2001; 125: 243–53
   PubMed Web of Science ®Google Scholar
• Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, Vogel P, et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med 1997; 121: 805–19
   PubMed Web of Science ®Google Scholar
• Ryabchikova EI, Kolesnikova LV, Luchko SV. An analysis of features of pathogenesis in two animal models of Ebola virus infection. J Infect Dis 1999; 179(Suppl 1)S199–202
   PubMed Web of Science ®Google Scholar
• Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, Topper M, et al. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 1996; 120: 140–55
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188: 1618–29
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Young HA, Jahrling PB, Davis KJ, Larsen T, Kagan E, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 2003; 163: 2371–82
   PubMed Web of Science ®Google Scholar
• Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930–5
   PubMed Web of Science ®Google Scholar
• Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002; 128: 163–8
   PubMed Web of Science ®Google Scholar
• Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729–35
   PubMed Web of Science ®Google Scholar
• Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. J Virol 1996; 70: 2208–14
   PubMed Web of Science ®Google Scholar
• Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques. Viral Immunol 2004; 17: 390–400
   PubMed Web of Science ®Google Scholar
• Gupta M, Greer P, Mahanty S, Shieh WJ, Zaki SR, Ahmed R, et al. CD8-mediated protection against Ebola virus infection is perforin dependent. J Immunol 2005; 174: 4198–202
   PubMed Web of Science ®Google Scholar
• Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, Pulendran B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003; 170: 2797–801
   PubMed Web of Science ®Google Scholar
• Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, Negley D, et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis 2003; 188: 1630–8
   PubMed Web of Science ®Google Scholar
• Daniel PT, Scholz C, Westermann J, Dorken B, Pezzutto A. Dendritic cells prevent CD95 mediated T lymphocyte death through costimulatory signals. Adv Exp Med. Biol 1998; 451: 173–7
   PubMed Web of Science ®Google Scholar
• Bosio CM, Moore BD, Warfield KL, Ruthel G, Mohamadzadeh M, Aman MJ, et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology 2004; 326: 280–7
   PubMed Web of Science ®Google Scholar
• Wahl-Jensen V, Kurz SK, Hazelton PR, Schnittler HJ, Stroher U, Burton DR, et al. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 2005; 79: 2413–9
   PubMed Web of Science ®Google Scholar
• Choe N, Tanaka S, Kagan E. Asbestos fibers and interleukin-1 up-regulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 1998; 19: 226–36
   PubMed Web of Science ®Google Scholar
• Kagan E, Geisbert TW, Li Y, Hensley LE, Jahrling PB. Ebola virus Zaire subtype can replicate and induce the formation of reactive nitrogen species in human bronchial epithelial cells. Am J Respir Crit Care Med 2003; 167(Suppl)A435
   Google Scholar
• Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis 2003; 188: 1613–7
   PubMed Web of Science ®Google Scholar
• Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391–405
   PubMed Web of Science ®Google Scholar
• Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278: 399–411
   PubMed Web of Science ®Google Scholar
• Brinton MA, Gavin EI, Lo WK, Pinto AJ, Morahan PS. Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection. Antiviral Res 1993; 20: 155–71
   PubMed Web of Science ®Google Scholar
• Charrel RN, de Lamballerie X. Arenaviruses other than Lassa virus. Antiviral Res 2003; 57: 89–100
   PubMed Web of Science ®Google Scholar
• Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1, 2 and inhibits infectivity of Ebola virus. Antiviral Res 2003; 58: 47–56
   PubMed Web of Science ®Google Scholar
• Bray M, Raymond JL, Geisbert T, Baker RO. 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected micev. Antiviral Res 2002; 55: 151–9
   PubMed Web of Science ®Google Scholar
• Bray M, Driscoll J, Huggins JW. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-l-homocysteine hydrolase inhibitor. Antiviral Res 2000; 45: 135–47
   PubMed Web of Science ®Google Scholar
• Vlasuk GP, Rote WE. Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc Med 2002; 12: 325–31
   PubMed Web of Science ®Google Scholar
• Lee A, Agnelli G, Buller H, Ginsberg J, Heit J, Rote W, et al. Dose–response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation 2001; 104: 74–8
   PubMed Web of Science ®Google Scholar
• Moons AH, Peters RJ, Bijsterveld NR, Piek JJ, Prins MH, Vlasuk GP, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol 2003; 41: 2147–53
   PubMed Web of Science ®Google Scholar
• Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179(Suppl 1)S18–23
   PubMed Web of Science ®Google Scholar
• Jahrling PB, Geisbert TW, Geisbert JB, Swearengen JR, Bray M, Jaax NK, et al. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J Infect Dis 1999; 179(Suppl 1)S224–34
   PubMed Web of Science ®Google Scholar
• Enserink M. Virology. New vaccine and treatment excite Ebola researchers. Science 2003; 302: 1141–2
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D, Roberts T, Custer D, Spik K, et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 1998; 246: 134–44
   PubMed Web of Science ®Google Scholar
• Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, et al. Immunization for Ebola virus infection. Nat Med 1998; 4: 37–42
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19: 142–53
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424: 681–4
   PubMed Web of Science ®Google Scholar
• Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 2001; 286: 384–90
   PubMed Web of Science ®Google Scholar
• Takada A, Feldmann H, Stroeher U, Bray M, Watanabe S, Ito H, et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 2003; 77: 1069–74
   PubMed Web of Science ®Google Scholar
• Brandt CD, Kim HW, Vargosko AJ, Jeffries BC, Arrobio JO, Rindge B, et al. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. Am J Epidemiol 1969; 90: 484–500
   PubMed Web of Science ®Google Scholar
• Jones, SM, Feldmann, H, Ströher, U, Geisbert, JB, Fernando, L, Grolla, A, , et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses, Nat Med 2005; 11: 786–90.
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003; 100: 15889–94
   PubMed Web of Science ®Google Scholar
• Vastag B. Ebola vaccines tested in humans, monkeys. JAMA 2004; 291: 549–50
   PubMed Web of Science ®Google Scholar